IBS

Arena Pharmaceuticals’ Selective CB2 Receptor Activator Drug Candidate Fights Pain in Irritable Bowel Syndrome
Arena Pharmaceuticals’ Selective CB2 Receptor Activator Drug Candidate Fights Pain in Irritable Bowel Syndrome
Xtalks
IBS
Arena Pharmaceuticals
cannabinoid type 2 receptors
Flag link:
4D pharma begins patient enrollment in Blautix IBS phase II study
4D pharma begins patient enrollment in Blautix IBS phase II study
Pharmaceutical Business Review
4D Pharma
IBS
clinical trials
Blautix
Flag link:
Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi
Ironwood steps up to challenge Valeant with Allergan's IBS med Viberzi
Fierce Pharma Marketing
Valeant Pharmaceuticals
Ironwood
Allergan
IBS
Viberzi
Flag link:
Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA
Valeant plots big DTC push for Xifaxan while rival Actavis drug waits on DEA
Fierce Pharma Marketing
Valeant Pharmaceuticals
DTC
Xifaxan
Actavis
IBS
Viberzi
Flag link:
FDA approves Actavis, Valeant drugs for irritable bowel syndrome
FDA approves Actavis, Valeant drugs for irritable bowel syndrome
Yahoo/Reuters
FDA
Actavis
Valeant Pharmaceuticals
IBS
irritable bowel syndrome
Xifaxan
Viberzi
Flag link:
AstraZeneca partner Ardelyx plunges after citing safety issue for lead drug
AstraZeneca partner Ardelyx plunges after citing safety issue for lead drug
Fierce Biotech
AstraZeneca
Ardelyx
tenapanor
IBS
Flag link:
Ardelyx irritable bowel syndrome drug succeeds in mid-stage trial
Ardelyx irritable bowel syndrome drug succeeds in mid-stage trial
Reuters
Ardelyx
IBS
irritable bowel syndrome
tenapanor
AstraZeneca Pharma India
Flag link:
New biotherapeutics drug for Crohn's to enter trials
New biotherapeutics drug for Crohn's to enter trials
Pharmaphorum
Crohn's Disease
IBS
Blautix
Thetanix
4D Pharma
Flag link:
Furiex irritable bowel syndrome drug succeeds in large trials
Furiex irritable bowel syndrome drug succeeds in large trials
Yahoo/Reuters
IBS
Furiex Pharmaceuticals
eluxadoline
IBS-d
Flag link:
Ironwood's Bowel Drug Sales Disappoint
Ironwood's Bowel Drug Sales Disappoint
TheStreet.com
Ironwood
Linzess
Forest Labs
irritable bowel syndrome
IBS
Flag link:
European Medicines Agency has recommendations for Novartis, Pfizer, Bristol-Myers Squibb and others
European Medicines Agency has recommendations for Novartis, Pfizer, Bristol-Myers Squibb and others
Pharma Times, UK
Pfizer
Bristol-Myers Squibb
Eliquis
stroke
IBS
Almirall
Novartis
Europe
Flag link:
Sucampo presents data for AMITIZA for treatment of IBS-C
Sucampo presents data for AMITIZA for treatment of IBS-C
Yahoo/Fly on the Wall
Sucampo
Amitiza
IBS
IBS-C
Flag link:
The FDA's Drug Approval Agenda for Next Week
The FDA's Drug Approval Agenda for Next Week
Seeking Alpha
FDA
Xifaxan
Salix
IBS
Remoxy
Durect Corporation
Pain Therapeutics
Pfizer
painkillers
Flag link:
FDA gives fast-track status to Tioga irritable bowel drug
FDA gives fast-track status to Tioga irritable bowel drug
San Diego Union Tribune, CA
irritable bowel syndrome
FDA
IBS
Tioga
fast track
Flag link:
Salix's IBS drug fails to get FDA nod
Salix's IBS drug fails to get FDA nod
Reuters
FDA
Salix
IBS
irritable bowel syndrome
Xifaxan
Flag link:
Salix Tanks After Drug Setback
Salix Tanks After Drug Setback
Minyanville
Salix
Xiafaxan
IBS
irritable bowel syndrome
Flag link:
Ironwood, Forest boast positive IBS drug trial
Ironwood, Forest boast positive IBS drug trial
Yahoo/AP
IBS
irritable bowel syndrome
Ironwood
Forest Labs
linaclotide
Flag link:
Lexicon says IBS drug met mid-stage study goal
Lexicon says IBS drug met mid-stage study goal
Yahoo/AP
IBS
irritable bowel syndrome
Lexicon Pharmaceuticals
Flag link: